Pyrazolopyrimidine Solid Dispersions for Solubility and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Substituted pyrazolopyrimidines, such as 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl) benzyl)-1H-pyrazolo[3,4-d]pyrimidine and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl) benzyl)-1H-pyrazolo[3,4-d]pyrimidine, exhibit limited solubility in aqueous environments at physiological pH and have less than optimal bioavailability, leading to unpredictable drug absorption and therapeutic effects.
Innovation Solution
The development of amorphous solid dispersions comprising these compounds dispersed in polymers such as hydroxypropyl methylcellulose acetate succinate (HPMCAS) and poly(methacrylic acid-co-methyl methacrylate) enhances solubility and bioavailability by stabilizing the amorphous form and preventing recrystallization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If substituted pyrazolopyrimidines are used in conventional crystalline form, then manufacturing is simple, but solubility in aqueous environments is limited and bioavailability is poor
Solution Approach 1:
The patent transforms the crystalline compound into an amorphous form, changing the physical state parameter from ordered crystalline structure to disordered amorphous structure. This parameter change increases solubility and bioavailability while maintaining manufacturing feasibility through solid dispersion technology
Solution Approach 2:
The patent creates a composite material system consisting of the pyrazolopyrimidine compound dispersed in a polymer matrix. This composite approach combines the therapeutic compound with a carrier polymer to achieve improved solubility and bioavailability properties that neither component possesses alone
2Reliability
If amorphous solid dispersions are created to improve solubility, then bioavailability increases, but formulation complexity increases
Solution Approach 1:
The patent uses a polymer as an intermediary carrier material that facilitates the dispersion and stabilization of the amorphous compound. The polymer acts as a mediator between the compound and the biological environment, enabling improved bioavailability while managing formulation complexity through selection of suitable polymer excipients
3Reliability
If amorphous solid dispersions are used to enhance solubility, then dose linearity improves, but stability against recrystallization must be maintained
Solution Approach 1:
The patent applies preliminary anti-action by incorporating stabilizing polymers and additives that prevent recrystallization before it can occur. The formulation includes components specifically selected to counteract the tendency of the amorphous compound to recrystallize, thereby maintaining dose linearity and compositional stability throughout storage and handling
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amorphous solid dispersions significantly improve oral bioavailability and dose linearity, providing stable formulations that maintain solubility and bioavailability over time, even under stress conditions.
Implementation Method 1
amorphous solid dispersions of substituted pyrazolopyrimidines are created by dispersing the compounds in polymers such as hydroxypropyl methylcellulose acetate succinate (HPMCAS) or Eudragit, which enhances solubility and stability, preventing recrystallization
Data Source
AI summary
Pharmaceutical formulations comprising substituted pyrazolopyrimidines are disclosed herein. Also disclosed are amorphous solid dispersions comprising substituted pyrazolopyrimidines, processes for preparing these amorphous solid dispersions, pharmaceutical compositions comprising such dispersions, and methods of use thereof.